Endothelin Receptor Antagonists in Kidney Disease
Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ET<sub>A</sub>) activation, causes sustained vasoconstriction...
Main Authors: | Irene Martínez-Díaz, Nerea Martos, Carmen Llorens-Cebrià, Francisco J. Álvarez, Patricia W. Bedard, Ander Vergara, Conxita Jacobs-Cachá, Maria José Soler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/4/3427 |
Similar Items
-
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
by: J. David Smeijer, et al.
Published: (2023-09-01) -
Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate Cancer
by: Ardavan Akhavan, et al.
Published: (2006-09-01) -
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
by: Jiří Patočka, et al.
Published: (2005-01-01) -
Endothelins: Vasoactive Peptids
by: Hasan Erdoğan, et al.
Published: (2013-08-01) -
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
by: Ander Vergara, et al.
Published: (2022-10-01)